Group 4 Medications - Blood related, under Framework Agreement CP 2023/304 of SPMS, for the Year 2026

This tender pertains to the procurement of "Group 4 Medications - Blood related" for the year 2026. The procurement is conducted under the framework agreement CP 2023/304, managed by SPMS (Serviços Partilhados do Ministério da Saúde - Shared Services of the Ministry of Health). This indicates that the contracting entity is leveraging an existing framework agreement to streamline the procurement process for these specific medications. "Group 4 Medications - Blood related" likely refers to a category of pharmaceuticals associated with blood products, blood disorders, or treatments affecting the blood system. The SPMS framework agreement suggests a centralized procurement mechanism designed to achieve economies of scale and ensure compliance with national health policies. The tender aims to secure the supply of these essential blood-related medications for the upcoming year. Bidders must adhere to the terms and conditions of the framework agreement and provide products that meet all quality and regulatory requirements. Further details regarding specific products within Group 4, quantities, and delivery schedules will be specified in the tender documentation associated with this framework agreement.

This is a supplies contract in the health and medical services and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 2,566.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.